Skip to Content

Lucentis (ranibizumab ophthalmic) Disease Interactions

There are 2 disease interactions with Lucentis (ranibizumab ophthalmic):

Major

Intravitreal injections (applies to Lucentis) ocular infections

Major Potential Hazard, High plausibility. Applicable conditions: Uveitis, Orbital Infection, Infectious Endophthalmitis, Infectious Optic Neuritis

Intravitreal administration, including those with aflibercept, pegaptanib, and ranibizumab is contraindicated in patients with active intraocular inflammation or ocular/periocular infections, since endophthalmitis can occur following the use of these injections. Patients should be advised to seek immediate medical attention from an ophthalmologist if the eye becomes red, photosensitive or painful, or if there is a change in vision in the days following the injection.

Moderate

Ranibizumab intravitreal injection (applies to Lucentis) increased intraocular pressure

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Glaucoma/Intraocular Hypertension

Increases in intraocular pressure have been reported both pre- injection and post- injection (at 60 minutes) while being treated with ranibizumab. Intraocular pressure should be monitored prior and following intravitreal injection with ranibizumab and managed appropriately.

Lucentis (ranibizumab ophthalmic) drug interactions

There is 1 drug interaction with Lucentis (ranibizumab ophthalmic)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.